Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Japan ETF (EWJ) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

iShares MSCI Japan ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Japan ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Japan ETF trades at $91.67, while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $96.26M). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

EWJINO
Sector
Broad Market / FactorHealth
52-Week High
$96.97$2.87
52-Week Low
$71.81$1.05
Market Cap
$96.26M
Enterprise Value
$67.27M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Japan ETF

EWJ, the iShares MSCI Japan ETF, trades at $91.92, down 2.1% on the day, with a bullish technical signal from moving averages but neutral oscillators. The fund provides exposure to Japanese equities amid a weakening yen, with news highlighting potential currency intervention by Japanese authorities and domestic investment pushes. Recent performance reflects Nikkei 225 volatility, trading near all-time highs before recent pullbacks.

Outlook hinges on yen stability and Japanese economic policies, with opportunities in hedged alternatives to mitigate currency risk. Risks include FX volatility, geopolitical tensions, and Japan's debt burden. Analyst sentiment is mixed, focusing on currency dynamics and equity market resilience.

Inovio Pharmaceuticals Inc

INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.

The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO